Identifying potential regulators of JAGGED1 expression in portal mesenchymal cells

Objective Portal mesenchymal cells induce the epithelial differentiation of the bile ducts in the developing liver via one of the Delta-Notch signaling components, JAGGED1. Although this differential induction is crucial for normal liver physiology as its genetic disorder (Alagille syndrome) causes jaundice, the molecular mechanism behind JAGGED1 expression remains unknown. Here, we searched for upstream regulatory transcription factors of JAGGED1 using an integrated bioinformatics method. Results According to the DoRothEA database, which integrates multiple lines of evidence on the relationship between transcription factors and their downstream target genes, three transcription factors were predicted to be upstream of JAGGED1: SLUG, SOX2, and EGR1. Among these, SLUG and EGR1 were enriched in ACTA2-expressing portal mesenchymal cells in two previously reported human fetal liver single-cell RNA-seq datasets. JAGGED1-expressing portal mesenchymal cells tended to express SLUG rather than EGR1, supporting that SLUG induced JAGGED1 expression. Together with the higher confidentiality of SLUG (DoRothEA level A) over EGR1 (DoRothEA level D), we concluded that SLUG was one of the most important candidate transcription factors upstream of JAGGED1. These results add mechanistic insights into the developmental biology of how portal mesenchymal cells support biliary development in the liver. Supplementary Information The online version contains supplementary material available at 10.1186/s13104-022-06058-4.


Introduction
Identification of the upstream regulators of key genes is one of the central issues in developmental biology. In the field of bile duct formation in the liver, one of the Delta-Notch signaling components, JAGGED1, is crucial, as understood by jaundice in patients with genetic abnormalities (Alagille syndrome) [1,2]. One of the major complications of this disease is abnormalities in the bile ducts in the liver, often requiring liver transplantation. JAGGED1 is expressed in portal mesenchymal cells that are characterized by smooth muscle actin-associated genes such as TAGLN [3] and ACTA2 [4]. From an experimental point of view, TAGLN-Cre-mediated JAGGED1 deletion in portal mesenchymal cells caused significant jaundice [3], suggesting that portal mesenchymal cells express JAGGED1 to induce epithelial differentiation that occurs in their periphery between mouse embryonic Days 13.5 (E13.5) and E18.5 [5]. However, the molecular mechanism underlying the induction of JAG-GED1 expression in portal mesenchymal cells remains unknown. As portal mesenchymal cells occupy a small percentage (less than 10%) of the total liver cells (discussed later), we considered that it would be difficult to identify potential upstream transcription factors using conventional biochemical methods. Given this, we went on to identify the upstream transcription factor regulating the induction of JAGGED1 expression in portal mesenchymal cells using an established bioinformatics database called DoRothEA [6]. DoRothEA uses several lines of data to generate a table of combinations of specific transcription factors and their downstream targets (regulons) with the confidentiality of these combinations scored from A (highest confidence) to E (lowest confidence), depending on the amount of evidence supporting these interactions. This means that a DoRothEA level A interaction is supported by at least two curated sources. We used this database to identify potential upstream transcription factors regulating JAGGED1 expression. We then examined the validity of these results by analyzing two sets of previously reported human fetal liver single-cell RNA-seq data [7]. This strategy of narrowing down the potential transcription factors provides realistic insights into the regulation of a developmentary important gene component, JAGGED1.
We used the raw FASTQ files of single-cell RNA sequencing data from human fetal livers at Carnegie Stages (CS) 20 (GSM3906001) and 23 (GSM3906002), which correspond to E14.5 and E16, respectively. Both datasets were retrieved from the NCBI Gene Expression Omnibus (https:// www. ncbi. nlm. nih. gov/ geo/). We used CellRanger (v5.0.1) [8] to align the sequencing reads in the FASTQ files to the human reference (GRCh38-2020-A, 10x Genomics) and created a count matrix for subsequent analysis. We used Scanpy (v1.7.0) [9] for basic filtering and comparing the enrichment of specific genes between one cluster and the others. Cells with high percentages of mitochondrial (> 0.1) or hemoglobin gene (> 0.1) expression and cells with a low percentage of ribosomal gene expression (< 0.05) were excluded from subsequent analysis. Any doublets identified by Scrublet (v0.2.3) were also excluded. Then, highly variable genes (n = 3019 and 2603 for CS20 and 23 datasets, respectively) across the single-cell datasets (n = 7028 and 8020 for CS20 and 23 datasets, respectively) were identified using the "sc.pp.highly_variable_genes" function and then subjected to dimension reduction with principal component analysis ("sc.tl.pca" function) and UMAP ("sc. tl.umap" function) before clustering (Leiden method). Single-cell RNA sequencing analysis was completed in Python 3.6.13 in an Ubuntu 20.04 LTS environment. We examined differences in gene expression within these clusters using the Mann-Whitney U test, with these outcomes described as FDR-adjusted p values in the Results section.

SLUG, SOX2, and EGR1 as potential regulators of JAGGED1
We first used DoRothEA to identify several potential regulators of JAGGED1 in portal mesenchymal cells and focused on SLUG (also known as SNAI2), SOX2, and EGR1, which are listed in the DoRothEA database for their association with JAGGED1 (levels A, B, and D, respectively) [6]. There were no candidate transcription factors with DoRothEA levels A or B other than SLUG and SOX2. EGR1 may be important because it was expressed in portal mesenchymal cells (discussed later), whereas the other transcription factors of DoRothEA level C or D, which are listed in Additional file 1, were not enriched in portal mesenchymal cells in either the CS20 or 23 datasets.

Identification of ACTA2-expressing portal mesenchymal cells
Next, we searched for TAGLN-expressing portal mesenchymal cells in previously reported single-cell RNAseq data from human fetal liver tissues of the CS20 and 23 datasets as described in the Methods section. Unfortunately, those cells occupied only 3.54% and 1.11% of the total cells of the CS20 and 23 datasets, respectively. Therefore, we alternatively searched for ACTA2-expressing portal mesenchymal cells in the CS20 and 23 datasets. In contrast to TAGLN, ACTA2-expressing cells occupied 5.92% and 5.76% of the total cells in the CS20 and 23 datasets, respectively, and we used ACTA2 as a portal mesenchymal cell marker gene. For the CS20 dataset, we conducted cell clustering as described in the Methods section, and that evaluation produced 21 clusters (Fig. 1a), one of which (cluster #6) contained 466 cells (6.63% of total cells) with increased ACTA2 (p = 8.21 × 10 -24 ) expression (Fig. 1b), identifying them as portal mesenchymal cells. As expected, this cell population expressed a relatively high level of JAGGED1 (log fold-change = 2.30, p = 0.439) (Fig. 1c). For the CS 23 dataset, these evaluations produced 19 clusters (Fig. 1d), one of which (cluster #15) contained 129 cells (4.96% of total cells) with increased ACTA2 (p = 1.80 × 10 -28 ) expression (Fig. 1e), identifying them as portal mesenchymal cells. Indeed, this cell population expressed a significantly high level of JAGGED1 (p = 0.0384) (Fig. 1f ).

Discussion
This study was designed to identify the upstream transcription factor regulating JAGGED1 expression in portal mesenchymal cells. Our evaluations found SLUG to be a central candidate for this regulatory role, as this protein is strongly expressed during the time frame associated with epithelial differentiation into portal mesenchymal cells. We considered that insignificant JAGGED1 expression in portal mesenchymal cells at CS20 was because this time point was relatively early to allow the expression of the upstream regulator, SLUG, rather than JAGGED1. SLUG reportedly acts as a transcriptional suppressor, as previously observed during the downregulation of E-cadherin expression in breast cancer [10]. However, the results of the biochemical analysis of the induction of fatty acid synthase in the liver suggest that SLUG can act as an activator [11]. Additionally, an in vitro study using a human breast cancer cell line (MCF7) showed that SLUG overexpression or siRNA-mediated suppression leads to increased or decreased JAGGED1 expression, respectively, suggesting that SLUG expression is positively correlated with JAGGED1 expression in this cell line [12]. Although this observation, along with the absence of SLUG binding sites in the JAG-GED1 promoter region according to DoRothEA [6], implies that SLUG does not directly regulate JAGGED1 expression, we propose that SLUG is located upstream of JAGGED1. EGR1 is also a potential regulator enriched in mesenchymal cells (cluster #6 of the CS20 dataset and cluster  #15 of the CS23 dataset). This transcription factor was reported to induce JAGGED1 expression in Leishmania donovani-infected bone marrow macrophages [13]. However, owing to its low confidentiality (DoRothEA level D) and scarce expression in JAGGED1-expressing portal mesenchymal cells in the CS23 dataset, we consider SLUG to be a potential regulator over EGR1.

Conclusion
SLUG is the candidate regulator of JAGGED1 in portal mesenchymal cells.

Limitations
First, further in vivo analysis is necessary to examine the biochemical properties of portal mesenchymal cells to determine the relationships between transcription factors and their regulons. Second, this study does not suggest that SLUG is the sole candidate for the upstream regulation of JAGGED1 expression because we only evaluated transcription factors according to DoRothEA. Third, four transcription factors (ESR1, HNB1B, PRDM14, and TFAP2C) were not examined for their enrichment because they were not differentially expressed genes in either CS20 or 23 datasets. Finally, we note that the molecular signature of portal mesenchymal cells is not fully characterized, and hence, other transcription factors may be listed as potential regulators when we use other marker genes for portal mesenchymal cells. However, we consider our work significant in that this is the first report on the molecular regulation of JAGGED1 expression in portal mesenchymal cells, which is important for normal liver physiology.